LAG3 and non-small cell lung carcinoma: As for patients with stage I–IIIB NSCLC with lymph node metastasis, the high expression of LAG-3 is associated with enhanced OS and DSS (disease-specific survival), which can also be considered a predictive factor of NSCLC lymph node metastasis, and LAG-3+ tumor-infiltrating lymphocytes can be used to significantly improve disease-specific survival (45); nevertheless, the mechanism through which LAG-3 exerts a negative effect on the immune response helps in improving OS, and disease-specific survival warrants further investigation.